Anti-Malarial Drugs Market Forecasts to 2030 – Global Analysis By Drug Type (Chloroquine, Quinine, Artemisinin-Based Combination Therapies (ACTs), Mefloquine, Primaquine and Other Drug Types), Drug Class, Malaria Type, Mode of Administration, Distribution

According to Stratistics MRC, the Global Anti-Malarial Drugs Market is accounted for $1044.1 million in 2024 and is expected to reach $1439.6 million by 2030 growing at a CAGR of 5.5% during the forecast period. Anti-Malarial Drugs are medications used to prevent or treat malaria, a parasitic infection caused by Plasmodium species. These drugs target the parasite at various stages of its lifecycle in the human body. Common anti-malarials include chloroquine, quinine, and artemisinin-based combination therapies (ACTs). They work by inhibiting parasite growth, replication, or survival within red blood cells. Anti-Malarial Drugs are crucial in malaria-endemic regions, where the disease poses a significant public health threat. They are also used for prophylaxis in travelers visiting high-risk areas.

According to the latest World Malaria Report, released in December 2021, there were an estimated 241 million cases of malaria and 627,000 resulting deaths worldwide in 2020. This represents about 14 million more cases in 2020 compared to 2019, and 69,000 more deaths.

Market Dynamics:

Driver:

Increasing healthcare expenditure

The increasing healthcare expenditure in the market is driven by rising malaria incidences and the growing demand for effective treatments. Governments and organizations are allocating more funds to combat malaria, focusing on improving access to these drugs in endemic regions. Enhanced research and development efforts, along with the need for innovative solutions, contribute to expanding the market, ensuring better healthcare infrastructure and more effective treatments worldwide.

Restraint:

Accessibility and affordability

Limited accessibility and affordability of Anti-Malarial Drugs can have severe negative effects on the market. In regions with economic challenges, high drug costs and inadequate healthcare infrastructure hinder timely treatment, leading to increased malaria-related mortality. Inconsistent access also fosters drug resistance, complicating treatment effectiveness. This disparity exacerbates public health crises, particularly in low-income and remote areas, preventing progress in controlling malaria and impeding overall market growth.

Opportunity:

High prevalence of malaria

The high prevalence of malaria significantly impacts the market, driving demand for effective treatments. Regions with a high burden of malaria, especially in sub-Saharan Africa and Southeast Asia, experience constant need for these drugs. The increasing number of cases prompts governments and health organizations to invest in drug accessibility, research, and distribution. This demand, coupled with rising resistance to existing treatments, further fuels market growth.

Threat:

Limited awareness and education

Limited awareness and education about malaria and its treatment can negatively impact the market. Lack of knowledge leads to improper use of drugs, contributing to resistance and reduced effectiveness. Inadequate understanding of prevention methods results in delayed treatment and higher transmission rates. This lack of education, especially in rural or remote areas, hinders demand for necessary drugs, slowing efforts to control malaria and impeding market growth.

Covid-19 Impact:

The COVID-19 pandemic disrupted the market by diverting resources and attention away from malaria control efforts. Supply chain interruptions, healthcare system strain, and limited access to drugs in malaria-endemic regions resulted in delays in treatment. Additionally, the pandemic sparked debates over the efficacy of certain Anti-Malarial Drugs for COVID-19, creating confusion and affecting their availability for malaria patients. This negatively impacted overall malaria treatment and market stability.

The quinine segment is expected to be the largest market share during the forecast period

The quinine segment is expected to account for the largest market share during the forecast period. Quinine remains a crucial anti-malarial drug in the market, particularly in severe cases of malaria. It is derived from the bark of the cinchona tree and has been used for centuries. Despite the emergence of newer drugs, quinine is still widely prescribed, especially in regions with drug resistance. Its affordability and effectiveness make it an essential treatment, especially when first-line therapies fail or in areas with limited access to advanced medications.

The hospitals segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the hospitals segment is predicted to witness the highest growth rate. They are key distribution points for anti-malarial medications, offering both inpatient and outpatient care. Hospitals contribute to market growth by ensuring proper diagnosis and administering effective drug regimens, including quinine and newer therapies. Their role is critical in malaria-endemic regions, where they help manage outbreaks, educate patients, and improve overall treatment access.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to the region's low malaria prevalence. However, it remains significant for travelers, military personnel, and healthcare professionals managing imported cases. North American pharmaceutical companies contribute to the global market by producing Anti-Malarial Drugs, and research focuses on drug resistance and innovative treatments. Governments also support malaria eradication initiatives in endemic countries, indirectly affecting the regional market dynamics.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. Countries such as India, China, and Indonesia report a substantial number of malaria cases annually, necessitating effective anti-malarial treatments. Ongoing initiatives to develop new drug combinations and formulations are contributing to market expansion. Additionally, These countries are major contributors to the market due to their large populations and high malaria incidence rates.

Key players in the market

Some of the key players in Anti-Malarial Drugs market include Novartis, Sanofi, GlaxoSmithKline, Bayer, Cipla, Mylan, Merck & Co., Lupin Pharmaceuticals, Teva Pharmaceutical Industries, Sumitomo Dainippon Pharma, Aurobindo Pharma, Dr. Reddy's Laboratories, Hetero Healthcare, Bharat Biotech, Takeda Pharmaceutical Company and Bausch Health.

Key Developments:

In December 2024, Aurobindo Pharma Ltd said its step-down subsidiary CuraTeQ Biologics s.r.o. has received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Bevqolva, its biosimilar version of bevacizumab..

In April 2024, Novartis and Medicines for Malaria Venture (MMV) announced positive data from their phase II/III CALINA study, demonstrating that a novel formulation of Coartem® (artemether-lumefantrine) developed for babies weighing less than 5kg with malaria has the required pharmacokinetic profile and good efficacy and safety.

Drug Types Covered:
• Chloroquine
• Quinine
• Artemisinin-Based Combination Therapies (ACTs)
• Mefloquine
• Primaquine
• Other Drug Types

Drug Classes Covered:
• Artemisinin
• Antifolate Drugs
• Cinchona Alkaloids
• Atovaquone-Proguanil

Malaria Types Covered:
• Plasmodium Falciparum
• Plasmodium Vivax
• Plasmodium Malaria
• Plasmodium Ovale

Mode of Administrations Covered:
• Oral
• Injectable/Intravenous
• Topical

Distribution Channels Covered:
• Government & NGO Programs
• Retail Pharmacies
• Online Pharmacies

End Users Covered:
• Hospitals
• Clinics and Health Centers
• Home Care Settings
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements